Clinic of Hospital Dentistry, Oral Oncology Unit, Dental School, University of Athens, Athens, Greece.
Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Aug;116(2):e110-6. doi: 10.1016/j.oooo.2013.02.022. Epub 2013 May 3.
We report the clinical features and management outcomes in 7 patients with everolimus-related stomatitis.
Fifteen women with hormone-receptor-positive advanced breast cancer receiving everolimus combined with exemestane were prospectively evaluated to assess the development of stomatitis. Oral ulcers were diagnosed based on established criteria.
Seven patients developed stomatitis (46.6%). All patients were treated with topical dexamethasone solution, while everolimus was temporarily discontinued in 4 patients. Stomatitis resolved within 1-2 weeks. Two of the 4 patients, who had interrupted everolimus, developed recurrent stomatitis following drug resume and everolimus was again discontinued and restarted after 2 weeks. To date, 5 patients receive everolimus in full dose. The 2 patients, who developed recurrent stomatitis, received a reduced dose.
Everolimus-related oral ulcers were frequent and led to dose modifications. Controlled trials, endorsing a consensus in terminology, are needed to evaluate measures on prevention and management of this unique toxicity.
我们报告了 7 例依维莫司相关性口腔炎患者的临床特征和治疗结果。
15 例接受依维莫司联合依西美坦治疗的激素受体阳性晚期乳腺癌女性患者前瞻性评估了口腔炎的发生情况。根据既定标准诊断口腔溃疡。
7 例患者发生口腔炎（46.6%）。所有患者均接受局部地塞米松溶液治疗，4 例患者暂时停用依维莫司。口腔炎在 1-2 周内缓解。4 例中断依维莫司的患者中，有 2 例在恢复用药后出现复发性口腔炎，再次停药 2 周后重新开始用药。迄今为止，5 例患者全剂量接受依维莫司治疗。2 例出现复发性口腔炎的患者接受了减量治疗。
依维莫司相关性口腔溃疡较为常见，并导致剂量调整。需要开展对照试验，以就该独特毒性的预防和管理达成共识。
